FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068754312> ?p ?o ?g. }

• W2068754312 endingPage "956" @default.
• W2068754312 startingPage "953" @default.
• W2068754312 abstract "Background: Rosiglitazone is a peroxisome proliferator–activated receptor (PPAR) gamma agonist that has shown promise as both an antiproliferative and redifferentiating agent for the treatment of thyroid cancer in preclinical studies. We investigated the efficacy and side effects of rosiglitazone therapy in patients with differentiated thyroid cancer of follicular cell origin that fails to take up radioiodine or is unresectable. Methods: Twenty patients with differentiated thyroid cancer were enrolled in an open-label, phase II trial of oral rosiglitazone treatment (4 mg daily for 1 week, then 8 mg daily for 7 weeks). Results: Five of 20 patients had a positive radioiodine scan after rosiglitazone treatment. Four patients had radioiodine uptake in the neck and one patient had uptake in the pelvis. Unstimulated thyroglobulin levels after rosiglitazone treatment increased in five patients, remained stable in 12 patients, and decreased in three patients. Seven patients had progressive disease on follow-up cross-sectional imaging; six patients in the size and number of lung metastasis and two patients in the size of the neck tumors. Overall, five patients had a partial response (decreased thyroglobulin or positive radioiodine uptake), three patients had stable disease (no change in thyroglobulin and radioiodine uptake status), and 12 patients had disease progression (increased thyroglobulin). By RECIST criteria, no patient had a complete or partial response to rosiglitazone treatment at 3 months follow-up. The mean follow-up time after protocol treatment was 12 months (median 12 months). Conclusions: Our findings suggest that rosiglitazone therapy may induce radioiodine uptake and reduce serum thyroglobulin levels in some patients with differentiated thyroid cancer but this did not result in clinically significant response on long-term follow-up. Moreover, no patients had response to rosiglitazone therapy by anatomic imaging studies." @default.
• W2068754312 created "2016-06-24" @default.
• W2068754312 creator A5019736472 @default.
• W2068754312 creator A5037814904 @default.
• W2068754312 creator A5064265390 @default.
• W2068754312 creator A5076916905 @default.
• W2068754312 creator A5078500931 @default.
• W2068754312 creator A5089773064 @default.
• W2068754312 date "2009-09-01" @default.
• W2068754312 modified "2023-09-30" @default.
• W2068754312 title "Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer" @default.
• W2068754312 cites W1670226482 @default.
• W2068754312 cites W1963663550 @default.
• W2068754312 cites W1978573623 @default.
• W2068754312 cites W1984962799 @default.
• W2068754312 cites W1985430208 @default.
• W2068754312 cites W1988862769 @default.
• W2068754312 cites W1990196512 @default.
• W2068754312 cites W2014271351 @default.
• W2068754312 cites W2021591676 @default.
• W2068754312 cites W2022282235 @default.
• W2068754312 cites W2048769469 @default.
• W2068754312 cites W2055051324 @default.
• W2068754312 cites W2057857957 @default.
• W2068754312 cites W2075923449 @default.
• W2068754312 cites W2080662424 @default.
• W2068754312 cites W2091334204 @default.
• W2068754312 cites W2165425723 @default.
• W2068754312 cites W2167256217 @default.
• W2068754312 cites W4231696134 @default.
• W2068754312 cites W4240908764 @default.
• W2068754312 cites W4244677469 @default.
• W2068754312 doi "https://doi.org/10.1089/thy.2008.0371" @default.
• W2068754312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19678746" @default.
• W2068754312 hasPublicationYear "2009" @default.
• W2068754312 type Work @default.
• W2068754312 sameAs 2068754312 @default.
• W2068754312 citedByCount "71" @default.
• W2068754312 countsByYear W20687543122012 @default.
• W2068754312 countsByYear W20687543122013 @default.
• W2068754312 countsByYear W20687543122014 @default.
• W2068754312 countsByYear W20687543122015 @default.
• W2068754312 countsByYear W20687543122016 @default.
• W2068754312 countsByYear W20687543122017 @default.
• W2068754312 countsByYear W20687543122018 @default.
• W2068754312 countsByYear W20687543122019 @default.
• W2068754312 countsByYear W20687543122020 @default.
• W2068754312 countsByYear W20687543122021 @default.
• W2068754312 countsByYear W20687543122022 @default.
• W2068754312 countsByYear W20687543122023 @default.
• W2068754312 crossrefType "journal-article" @default.
• W2068754312 hasAuthorship W2068754312A5019736472 @default.
• W2068754312 hasAuthorship W2068754312A5037814904 @default.
• W2068754312 hasAuthorship W2068754312A5064265390 @default.
• W2068754312 hasAuthorship W2068754312A5076916905 @default.
• W2068754312 hasAuthorship W2068754312A5078500931 @default.
• W2068754312 hasAuthorship W2068754312A5089773064 @default.
• W2068754312 hasConcept C126322002 @default.
• W2068754312 hasConcept C126894567 @default.
• W2068754312 hasConcept C134018914 @default.
• W2068754312 hasConcept C170493617 @default.
• W2068754312 hasConcept C2778835679 @default.
• W2068754312 hasConcept C2779341817 @default.
• W2068754312 hasConcept C2779761222 @default.
• W2068754312 hasConcept C2780152017 @default.
• W2068754312 hasConcept C2781461381 @default.
• W2068754312 hasConcept C526584372 @default.
• W2068754312 hasConcept C71924100 @default.
• W2068754312 hasConcept C90924648 @default.
• W2068754312 hasConceptScore W2068754312C126322002 @default.
• W2068754312 hasConceptScore W2068754312C126894567 @default.
• W2068754312 hasConceptScore W2068754312C134018914 @default.
• W2068754312 hasConceptScore W2068754312C170493617 @default.
• W2068754312 hasConceptScore W2068754312C2778835679 @default.
• W2068754312 hasConceptScore W2068754312C2779341817 @default.
• W2068754312 hasConceptScore W2068754312C2779761222 @default.
• W2068754312 hasConceptScore W2068754312C2780152017 @default.
• W2068754312 hasConceptScore W2068754312C2781461381 @default.
• W2068754312 hasConceptScore W2068754312C526584372 @default.
• W2068754312 hasConceptScore W2068754312C71924100 @default.
• W2068754312 hasConceptScore W2068754312C90924648 @default.
• W2068754312 hasIssue "9" @default.
• W2068754312 hasLocation W20687543121 @default.
• W2068754312 hasLocation W20687543122 @default.
• W2068754312 hasOpenAccess W2068754312 @default.
• W2068754312 hasPrimaryLocation W20687543121 @default.
• W2068754312 hasRelatedWork W1965393911 @default.
• W2068754312 hasRelatedWork W1965765907 @default.
• W2068754312 hasRelatedWork W1972113515 @default.
• W2068754312 hasRelatedWork W2014113220 @default.
• W2068754312 hasRelatedWork W2041969270 @default.
• W2068754312 hasRelatedWork W2077738040 @default.
• W2068754312 hasRelatedWork W2126085844 @default.
• W2068754312 hasRelatedWork W2748952813 @default.
• W2068754312 hasRelatedWork W2889248919 @default.
• W2068754312 hasRelatedWork W3185405440 @default.
• W2068754312 hasVolume "19" @default.
• W2068754312 isParatext "false" @default.

• next